XVIVO Perfusion AB

XVIVO Perfusion AB is a Sweden-headquartered leader in ex-vivo organ preservation and perfusion technologies for transplantation. The company develops and commercializes machine perfusion systems and consumables designed to extend organ preservation time, increase organ utilization, enable organ assessment, and improve transplant outcomes. Core product lines include Kidney Assist Transport™ (hypothermic pulsatile perfusion device for donor kidneys, up to 24 hours preservation), Liver Assist™ (multi-protocol perfusion platform supporting hypothermic HOPE/DHOPE, normothermic, and sub-normothermic protocols), XPS™ (comprehensive ex-vivo lung perfusion platform for assessment and preservation), and PERFADEX® Plus (standard lung preservation solution used by >90% of transplantation clinics). The company also provides full-service organ recovery services including technology, logistics, staffing, and clinical support. XVIVO serves transplantation centers, organ procurement organizations, and research institutions globally. The company is publicly traded on Nasdaq Stockholm and maintains regulatory compliance through CE marking and FDA submissions (including 510(k) pathway for novel perfusion devices). XVIVO Academy provides clinical training, webinars, and educational resources to support adoption and optimization of organ perfusion protocols.